Cargando…

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

BACKGROUND: Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. METHODS: Using the French national multicenter ESME (Epi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertho, Marion, Fraisse, Julien, Patsouris, Anne, Cottu, Paul, Arnedos, Monica, Pérol, David, Jaffré, Anne, Goncalves, Anthony, Lebitasy, Marie-Paule, D’Hondt, Véronique, Dalenc, Florence, Ferrero, Jean-Marc, Levy, Christelle, Dabakuyo, Sandrine, Rouzier, Roman, Penault-Llorca, Frédérique, Uwer, Lionel, Eymard, Jean-Christophe, Breton, Mathias, Chevrot, Michaël, Thureau, Sébastien, Petit, Thierry, Simon, Gaëtane, Frénel, Jean-Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841864/ https://www.ncbi.nlm.nih.gov/pubmed/33613700 http://dx.doi.org/10.1177/1758835920987657

Ejemplares similares

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
por: Grinda, Thomas, et al.
Publicado: (2021)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Practical ESM analysis
por: Robertson, Sue
Publicado: (2019)

The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
por: Pérol, David, et al.
Publicado: (2019)

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
por: Augereau, Paule, et al.
Publicado: (2017)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
por: Curtit, Elsa, et al.
Publicado: (2023)

Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project
por: Ezzalfani, Monia, et al.
Publicado: (2021)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
por: Gougis, P., et al.
Publicado: (2019)

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
por: de Moura, Alexandre, et al.
Publicado: (2023)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
por: Franchet, Camille, et al.
Publicado: (2021)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
por: Bini, Marta, et al.
Publicado: (2022)

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2019)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

User's guide to ESME version 7.3 at CERN
por: Hancock, S, et al.
Publicado: (1992)

User’s guide to ESME version 7.3 at CERN
por: Hancock, S, et al.
Publicado: (1992)

Radar Position Estimation by Sequential Irradiation of ESM Receivers
por: Hubáček, Petr, et al.
Publicado: (2021)

Investor demand in syndicated EFSF/ESM bond issuances
por: Hillebrand, Martin, et al.
Publicado: (2023)

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
por: Dano, D., et al.
Publicado: (2021)

War and memory in 'For Ésme-With loce and Squalor ' by J.D. Salinger/
por: Córdova Hoyos, Ana Paola
Publicado: (2012)

Endometriosis of the skeletal muscular system (ESMS): a systematic review
por: Ye, Hui, et al.
Publicado: (2023)

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
por: Alhenc-Gelas, Marion, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Identification of ESM1 overexpressed in head and neck squamous cell carcinoma
por: Xu, Hongbo, et al.
Publicado: (2019)

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience
por: Lamy, Tina, et al.
Publicado: (2021)

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna(®) Test in the management of early-stage breast cancers
por: Hequet, Delphine, et al.
Publicado: (2017)

Correction: Sato, K., et al. Identification of a Novel Oligosaccharide in Maple Syrup as a Potential Alternative Saccharide for Diabetes Mellitus Patients. Int. J. Mol. Sci. 2019, 20, 5041
por: Sato, Kanta, et al.
Publicado: (2020)

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer
por: Raoul, Jean-Luc, et al.
Publicado: (2021)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
por: Raoul, Jean-Luc, et al.
Publicado: (2022)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database
por: Mailliez, Audrey, et al.
Publicado: (2022)

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2017)

Engagement, Persistence, and Gender in Computer Science: Results of a Smartphone ESM Study
por: Milesi, Carolina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cb7r767pk118a63thsib48ph6t